Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchid PharmaLUX:ORCHP 56 Debt-to-Equity is 0.28 as of Mar. 2026, which is 33% above its 10-year median of 0.21. GuruFocus rates LUX:ORCHP with a GF Score™ of 56/100 and a GF Value™ of $4.68. The stock has 10 warning signs investors should review. Among 812 Drug Manufacturers companies, Orchid Pharma ranks worse than 50.12% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Orchid Pharma's Debt-to-Equity or its related term are showing as below:
LUX:ORCHP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -6.66 Med: 0.21 Max: 0.74
Current: 0.28
During the past 13 years, the highest Debt-to-Equity Ratio of Orchid Pharma was 0.74. The lowest was -6.66. And the median was 0.21.
LUX:ORCHP's Debt-to-Equity is ranked worse than 50.12% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs LUX:ORCHP: 0.28
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Orchid Pharma Debt-to-Equity Related Terms
Orchid Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma (LUX:ORCHP) has a Debt-to-Equity of 0.28 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Orchid Pharma and its competitors. This is 33% above median its historical median of 0.21. According to the industry distribution chart, Orchid Pharma ranks #407 out of 812 companies in the Drug Manufacturers industry, placing it in the top 50.1%.
Is Orchid Pharma's Debt-to-Equity too high?
Orchid Pharma's current Debt-to-Equity of 0.28 is 33% above median its 10-year median of 0.21. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Orchid Pharma's value of 0.28 is 1.8% above this industry median. Based on the distribution chart, Orchid Pharma ranks #407 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orchid Pharma has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #407 out of 812 companies for Debt-to-Equity. This places Orchid Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Orchid Pharma's value of 0.28 is 1.8% above this benchmark. While the company's 10-year median is 0.21 vs. the industry median of 0.28, Orchid Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchid Pharma's current Debt-to-Equity of 0.28 is 1.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Orchid Pharma and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current Debt-to-Equity is 0.28, which is 33% above median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Debt-to-Equity of 0.28. The stock's GF Value™ is $4.68, compared to a current price of $5.45 — trading 16.5% above its estimated fair value. The current Debt-to-Equity is 0.28, which is 33% above median its 10-year median of 0.21 and 1.8% above the Drug Manufacturers industry median of 0.28. Orchid Pharma's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Debt-to-Equity is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 16.5% above its estimated GF Value™ of $4.68.
Key valuation signals for LUX:ORCHP:
Debt-to-Equity: 0.28 (33% above median its 10-year median of 0.21)
GF Value™: $4.68 vs. price of $5.45 (16.5% above fair value)
Industry Position: 1.8% above the Drug Manufacturers median (#407 of 812)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
56GF Score
Get the complete analysis for LUX:ORCHP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
